


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Gholam Peyman	
(37 CFR 1.98(b))		(Use several sheets if necessary)				FILING DATE July 31, 2003	GROUP 1615



U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		PATENT NUMBER			ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Q/S	A.A	4	0	7	9	0	3	8	03/14/78 Choi et al.
	A.B	4	0	9	3	7	0	9	06/06/78 Choi et al.
	A.C	4	1	3	1	6	4	8	12/26/78 Choi et al.
	A.D	4	1	3	8	3	4	4	02/06/79 Choi et al.
	A.E	4	1	8	0	6	4	6	12/25/79 Choi et al.
	A.F	4	3	0	4	7	6	7	12/08/81 Heller et al.
	A.G	4	9	4	6	9	3	1	08/07/90 Heller et al.
	A.H	5	2	9	4	6	0	4	03/15/94 Nussenblatt et al.
	A.I	5	4	1	1	9	5	2	05/1995 Kaswan
	A.J	5	4	5	7	1	8	2	10/10/95 Wiederrecht et al.
Q/S	A.K	5	7	7	0	6	0	7	06/23/98 Honbo et al.

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
Q/S	A.L	JP 07010752 Abstract	01/13/95	JP	A61K	31/365	N/A
Q/S	A.M	JP 09315954 Abstract	12/09/97	JP	A61K	9/08	N/A
Q/S	A.N	WO 99/22722	05/14/99	PCT WO	A61K	31/00	N/A
	A.O	AU 17388/88	Unknown	AU	Unknown	Unknown	N/A
	A.P	AU 20350/92	Unknown	AU	Unknown	Unknown	N/A
Q/S	A.Q	CN 1333018	01/30/02	CN	A61K	9/06	Abstract only

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

Q/S	A.R	Algvere et al., <u>Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD</u> , European J of Ophthalmology (1999) 9(3):217-230
Q/S	A.S	Anderson et al., <u>A Role for Local Inflammation in the Formation of Drusen in the Aging Eye</u> , American Journal of Ophthalmology, Vol. 134, No. 3, September 2002, pp. 411-431
Q/S	A.T	Aramant et al., <u>Retinal transplantation</u> , Science & Medicines (2000), 7:20-29

EXAMINER	DATE CONSIDERED
<i>Marcia J. Reink</i>	02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))						APPLICANT Gholam Peyman	
								FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Q/S	B.A	5	7	7	3	0	1	9	08/30/98	Ashton et al	424	423	09/27/95
	B.B	5	9	5	2	3	7	1	09/14/99	Baker et al.	514	443	10/08/97
	B.C	5	9	6	8	5	4	3	10/19/99	Heller et al.	424	425	12/05/97
	B.D	6	0	0	4	5	6	5	12/21/99	Chiba et al.	424	278.1	09/23/97
	B.E	6	1	7	9	8	1	7	01/30/01	Zhong	604	265	01/28/99
	B.F	6	2	3	9	1	1	3	05/29/01	Dawson et al.	514	29	06/02/99
	B.G	6	2	3	8	7	9	9	05/29/01	Opolski	428	423	02/07/97
	B.H	6	2	5	8	8	5	6	07/10/01	Chamberlain et al	514	912	07/10/01
	B.I	6	3	0	6	4	2	2	10/23/01	Batich et al	424	423	08/03/98
	B.J	6	3	5	0	4	4	2	02/26/02	Garst	424	78.04	05/30/01
Q/S	B.K	6	4	1	3	5	3	6	07/02/02	Gibson et al	424	423	08/27/99

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
Q/S	B.L	CN 1340358	03/20/03	CN	A61K	38/13	Abstract only
	B.M	CN 1456350	11/19/2003	CN	A61K	9/00	Abstract only
	B.N	DE 19810655	09/16/99	DE	A61K	38/13	Abstract only
	B.O	EP 1142566	10/10/01	EP	A61K	9/08	Abstract only
	B.P	JP 10218787	08/18/98	JP	A61K	38/22	Yes
Q/S	B.Q	JP 1997030966	02/04/97	JP	A61K	31/365	Yes

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

Q/S	B.R	Aron-Rosa, <u>Pulsed Nd:YAG lasers in ophthalmology</u> , Nd:YAG Laser Applications pp. 34-48 (1986)
Q/S	B.S	Carmo et al., <u>Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotocin-induced diabetes</u> , Mediators of Inflammation (2000), 9(5):243-248
Q/S	B.T	Chiou, <u>Topical Treatment of Ocular Hypertension, Glaucoma, Ischemic Retinopathy and Age-Related Macular Degeneration with Ophthalmic Formulation of Dopamine Antagonists</u> , U.S. Patent Publication No. US 2003/0069232, published 04/10/03

EXAMINER		DATE CONSIDERED
	<i>Junaea Y. Reina</i>	02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))						APPLICANT Gholam Peyman	
								FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>Q/S</i>	C.A	6	4	3	6	9	0	6	08/20/02	Or et al	514	29	04/02/01
<i>Q/S</i>	C.B	6	4	4	0	9	4	2	08/27/02	Or et al	514	30	12/22/00
	C.C	6	4	6	2	0	7	1	10/2002	Castillejos	—	—	
	C.D	6	4	6	2	0	2	6	10/08/02	Or et al	514	30	02/16/01
	C.E	6	4	8	2	7	9	9	11/2002	Tuse et al	—	—	
	C.F	6	5	3	4	6	9	3	03/18/03	Fischell et al.	A61F	13/00	01/31/01
	C.G	6	5	9	6	2	9	6	07/22/03	Nelson et al	424	425	08/04/00
	C.H	6	6	1	3	3	5	5	09/02/03	Ng et al	424	462	05/11/01
	C.I	6	6	1	7	3	4	5	09/09/03	Gregory et al	514	395	09/12/00
	C.J	6	6	6	7	3	7	1	12/23/03	Ng et al	525	462	11/14/02
<i>Q/S</i>	C.K	6	6	7	0	3	9	8	12/2003	Edwards et a	—	—	

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>Q/S</i>	C.L	JP 2001064198	03/13/01	JP	A61K	38/22	Yes
<i>Q/S</i>	C.M	WO 02/24234	03/28/02	PCT WO	A61K	48/00	N/A
<i>Q/S</i>	C.N	WO 03/051385	06/26/03	PCT WO	A61K	38/13	Abstract only
<i>Q/S</i>	C.O	WO 03/017990	03/06/03	PCT WO	A61K	31/00	N/A
<i>Q/S</i>	C.P	WO 2004/096261	11/11/24	PCT WO	A61K	38/13	Abstract only
<i>Q/S</i>	C.Q	WO 2004/043480	05/27/04	PCT WO	A61K	38/00	N/A

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>Q/S</i>	C.R	Cicciarelli et al., <u>Pharmacokinetics of subconjunctivally administered cyclosporine A. Local delivery prior to chemotherapy for retinoblastoma</u> , IOVS (3/15/2001), 42(4):S332
<i>Q/S</i>	C.S	Costantini, LC, et al., <u>Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture</u> , Experimental Neurology 164,60-70 (2000)
<i>Q/S</i>	C.T	Das et al., <u>The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study</u> , Experimental Neurology (1999), 157:58-68

EXAMINER	<i>Damear Y. Reeth</i>	DATE CONSIDERED	<i>02/24/06</i>
----------	------------------------	-----------------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
									APPLICANT Gholam Peyman	
									FILING DATE July 31, 2003	GROUP 1615
(37 CFR 1.98(b))										

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>GP</i>	D.A	6	6	7	3	8	0	7	01/2004	Sakai et al	—	—
<i>GP</i>	D.B	6	7	1	3	0	8	1	03/2004	Robinson et al	—	—
	D.C											
	D.D											
	D.E											
	D.F											
	D.G											
	D.H											
	D.I											
	D.J											
	D.K											

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>GP</i>	D.L	WO 2005/030205	04/07/05	PCT WO	A61K	31/436	N/A
<i>GP</i>	D.M	WO 2005/011813	02/10/05	PCT WO	A61P	27/02	N/A
<i>GP</i>	D.N	WO 89/01772	03/02/89	PCT WO	A61K	9/00	N/A
<i>GP</i>	D.O	WO 99/42104	08/26/99	PCT WO	A61K	31/435	N/A
	D.P						
	D.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>GP</i>	D.R	Del Cerro et al., <u>Histologic correlation of human neural retinal transplantation</u> , Invest. Ophthalmology & Visual Science (2000) 41(10): 3142-3148
<i>GP</i>	D.S	Dewey, 2003 PCO Update: Part 1 - How the square-edged IOL prevents posterior capsular opacification, Cataract & Refractive Surgery Today, September 2003, pp. 20-22
<i>GP</i>	D.T	Donnenfeld et al., <u>Cyclosporine provides effective treatment for dry eye</u> , Therapeutic Updates in Ophthalmology, Special Issue, July 1999, pp. 1-3

EXAMINER	DATE CONSIDERED
<i>Anneka N. Deard</i>	02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))				APPLICANT Gholam Peyman	
				FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
E.A							
E.B							
E.C							
E.D							
E.E							
E.F							
E.G							
E.H							
E.I							
E.J							
E.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
E.L							
E.M							
E.N							
E.O							
E.P							
E.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	E.R	Eneydi et al., <u>Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and dexamethasone (DEX)</u> , Investigative Ophthalmology and Visual Science, Vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994 abstract
	E.S	Enyedi et al., <u>An intravitreal device providing sustained release of cyclosporine and dexamethasone</u> , Current Eye Research, May 1996, Vol. 15, No. 5, pp. 549-557
	E.T	Garweg et al., <u>Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine</u> , Klinische Monatsblatter fur Augenheilkunde, Vol. 199, No. 3, September 1991, pp. 199-205

EXAMINER		DATE CONSIDERED
----------	---	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))				APPLICANT Gholam Peyman	
				FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
F.A							
F.B							
F.C							
F.D							
F.E							
F.F							
F.G							
F.H							
F.I							
F.J							
F.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
F.L							
F.M							
F.N							
F.O							
F.P							
F.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>✓</i>	F.R	Gilbard, EW Interview: Electrolyte balance is key to dry-eye product's success, EyeWorld, February 1999, pp. 20ff
<i>✓</i>	F.S	Grisolano et al., Retinal Toxicity Study of Intravitreal Cyclosporin, Ophthalmic Surgery, March 1986, 17:155-156
<i>✓</i>	F.T	Hageman et al., Diagnostics and Therapeutics for Macular Degeneration-Related Disorders, U.S. Patent Application Publication No. US 2-2/0015957, published 02/07/02
EXAMINER <i>Chunmei Chen Ph.D.</i>	DATE CONSIDERED	02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Gholam Peyman	
(37 CFR 1.98(b))		(Use several sheets if necessary)		FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
G.A							
G.B							
G.C							
G.D							
G.E							
G.F							
G.G							
G.H							
G.I							
G.J							
G.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
G.L							
G.M							
G.N							
G.O							
G.P							
G.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>Q/S</i>	G.R	Jiang et al, Corneal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats, Invest. Ophthalmology & Visual Science (1994). 35(13):4300-4308
<i>Q/S</i>	G.S	Karacorlu et al, Lack of toxicity of intravitreally administered interferon Alpha-2a, Ophthalmic Surgery (1999) 23:833-835
<i>Q/S</i>	G.T	Keep et al, Introduction: Immunosuppressants as Neuroprotective Agents, Immunosuppressant Analogs in Neuroprotection, Part I: Immunosuppressants, Neuropathic Disorders, and Neuroprotection, Ed. Borlongan & Sanberg, Humana Press Inc., Totowa NJ, pp.3-32 <i>(11/2002)</i>

EXAMINER	<i>Yvonne N. Reid</i>	DATE CONSIDERED
----------	-----------------------	-----------------

*02/24/06*

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Gholam Peyman	
(37 CFR 1.98(b))		(Use several sheets if necessary)		FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A							
	H.B							
	H.C							
	H.D							
	H.E							
	H.F							
	H.G							
	H.H							
	H.I							
	H.J							
	H.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>Q6</i>	H.R	Kiryu et al., <u>In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury</u> , Poster Presentation 1247-B128	<i>(03/1998)</i>
<i>Q8</i>	H.S	Lai et al., <u>Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer</u> , IOVS (9/2000) 41(10):3134-3141	
<i>Q8</i>	H.T	Lallemand et al., <u>Cyclosporine A delivery to the eye: A pharmaceutical challenge</u> , European Journal of Pharmaceutics and Biopharmaceutics, 56 (2003), pp. 307-318	

EXAMINER

*Amber M. Druh*

DATE CONSIDERED

*02/24/06*

EXAMINER: Initial if citation considered; whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Gholam Peyman	
(Use several sheets if necessary) (37 CFR 1.98(b))				FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
I.A							
I.B							
I.C							
I.D							
I.E							
I.F							
I.G							
I.H							
I.I							
I.J							
I.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
I.L							
I.M							
I.N							
I.O							
I.P							
I.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>Q/S</i>	I.R	Lipner, Dry Eye 101: Developing etiologies and treatments for this widespread syndrome, EyeWorld, February 1999, pp. 19ff
<i>Q/S</i>	I.S	Lipper et al., Recent therapeutic advances in dermatology, JAMA, Vol. 283, No. 2, January 12, 2000, pp. 175-177
<i>Q/S</i>	I.T	Lopez et al., Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS, Invest. Ophthalmology & Visual Science (1989), 30:586-588

EXAMINER	<i>Alunera Y. Dreith</i>	DATE CONSIDERED
		02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))				APPLICANT Gholam Peyman	
				FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J.A							
J.B							
J.C							
J.D							
J.E							
J.F							
J.G							
J.H							
J.I							
J.J							
J.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
J.L							
J.M							
J.N							
J.O							
J.P							
J.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>gjs</i>	J.R	Lund, et al., <u>Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats</u> , PNCS (2001), 98(17): 9942-9947
<i>gjs</i>	J.S	Martin DF et al., <u>Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune Uveoretinitis</u> . The Journal of Immunology, 1995, 154:922-927
<i>gjs</i>	J.T	Nicoletti et al., <u>The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats</u> , Scandinavian Journal of Immunology (1992) 36(3):415-420

EXAMINER

*Anneka J. Reich*

DATE CONSIDERED

02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.  
Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Gholam Peyman	
(37 CFR 1.98(b))		(Use several sheets if necessary)		FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	K.A						
	K.B						
	K.C						
	K.D						
	K.E						
	K.F						
	K.G						
	K.H						
	K.I						
	K.J						
	K.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	K.L						
	K.M						
	K.N						
	K.O						
	K.P						
	K.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>GS</i>	K.R	Passos et al., <u>Ocular Toxicity of Intravitreal Tacrolimus</u> , Ophthalmic Surgery and Lasers, March/April 2002, Vol. 22, No. 2, pp. 140-144
<i>GS</i>	K.S	PCT, <u>International Search Report</u> , PCT/US03/28315, mailed 06/15/04, 6 pages
<i>GS</i>	K.T	Peyman et al., <u>Intravitreal Surgery, Principles and Practice</u> , 2nd Edition, 1994, Ppletton & Lange, Connecticut, pp. 443-452

EXAMINER	<i>Junera Y. Preish</i>	DATE CONSIDERED
		02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003	GROUP 1615		

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
L.A							
L.B							
L.C							
L.D							
L.E							
L.F							
L.G							
L.H							
L.I							
L.J							
L.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
L.L							
L.M							
L.N							
L.O							
L.P							
L.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>Q/S</i>	L.R	Peyman et al., <u>Keratitis (Noninfectious)</u> , Principles and Practice of Ophthalmology, W.B. Saunders Company, 1980, pp. 446-449
<i>Q/S</i>	L.S	Peyman et al., <u>Intravitreal drug therapy</u> , Japanese Journal of Ophthalmology (1989), 33(4): 392-404
<i>Q/S</i>	L.T	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2004/0092435, published 05/13/04, Serial No. 10/289,772, filed 11/07/02
EXAMINER	<i>Yumea Y. Preuk</i>	DATE CONSIDERED 02/26/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))			APPLICANT Gholam Peyman	
					FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	M.A						
	M.B						
	M.C						
	M.D						
	M.E						
	M.F						
	M.G						
	M.H						
	M.I						
	M.J						
✓	M.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	M.L						
	M.M						
	M.N						
	M.O						
	M.P						
	M.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>✓</i>	M.R	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03
<i>✓</i>	M.S	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063997, published 03/24/05, Serial No. 10/752,124, filed 01/06/04
<i>✓</i>	M.T	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063996, published 03/24/05, Serial No. 10/667,161, filed 09/19/03,

EXAMINER	DATE CONSIDERED	
<i>Numeria Y. Dreish</i>	<i>02/24/06</i>	

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))					APPLICANT Gholam Peyman	
					FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	N.A						
	N.B						
	N.C						
	N.D						
	N.E						
	N.F						
	N.G						
	N.H						
	N.I						
	N.J						
	N.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	N.L						
	N.M						
	N.N						
	N.O						
	N.P						
	N.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>GP</i>	N.R	Peyman, <u>Pupillary Membranes: Nd'YAG Capsulotomy</u> , Intravitreal Surgery, Norwalk CT, Appleton & Lange, 1994, pp. 253-257
<i>GP</i>	N.S	Peyman et al., <u>Implantation of a sustained-release ganciclovir implant</u> , Vitreoretinal Surgical Techniques, Martin Dunitz Ltd., 2001, Chapter 45, pp. 521-531
<i>GP</i>	N.T	Schonfeld and Kirst, <u>Macrolide Antibiotics</u> , Birkhäuser, Basel, Switzerland, 2002, pp. 1-36

EXAMINER

*Yuneca H. Reid*

DATE CONSIDERED

*02/24/06*

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Gholam Peyman	
(37 CFR 1.98(b))		(Use several sheets if necessary)		FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
O.A							
O.B							
O.C							
O.D							
O.E							
O.F							
O.G							
O.H							
O.I							
O.J							
O.K							


## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
O.L							
O.M							
O.N							
O.O							
O.P							
O.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	O.R	Shen et al., <u>Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina</u> , Archives of Ophthalmology (7/2001), 119(7): 1033-1043
	O.S	Stosic-Grujicic et al, <u>Leflunomide protects mice from multiple low dose streptozotocin (MLD-SA)-induced insulitis and diabetes</u> , Clinical & Experimental Immunology (1999) 117(1):44-50
	O.T	Ueno, <u>Composition for Topical Administration</u> , U.S. Patent Application Publication No. US2003/0044452 published 03/06/03, Serial No. 10/187,013, filed 07/02/02

EXAMINER



DATE CONSIDERED

02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.  
 Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))				APPLICANT Gholam Peyman	
				FILING DATE July 31, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
P.A							
P.B							
P.C							
P.D							
P.E							
P.F							
P.G							
P.H							
P.I							
P.J							
P.K							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
P.L							
P.M							
P.N							
P.O							
P.P							
P.Q							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	P.R	Wakelee-Lynch, Interferon may offer first drug therapy for diabetic retinopathy, Diabetes Care (1992), 15(2):300-301
	P.S	Wise, Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, New York, 2000
	P.T	

EXAMINER		DATE CONSIDERED	02/24/06
----------	---	-----------------	----------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.